Additional file 7: Table S7. Proteins identification (NR, PR and TR)

Alex-Ane Mathieu (5099165)

AnaĂŻs Chauvin (5099171)

Chang-Shu Wang (5099159)

FranĂ§ois-Michel Boisvert (5099168)

Perrine Garde-Granger (3767791)

Sameh Geha (3524294)

Vincent Lacasse (5099162)

Clinical Proteomics

Additional file 4: Table S4. Proteins differentially expressed between PR and PR

FigShare

MOESM4 of The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature

Additional file 6: Table S6. Proteins differentially expressed between non-responders (NR + PR) and total responders (TR)

Anaïs Chauvin (5099261)

François-Michel Boisvert (444453)

MOESM6 of The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature

MOESM7 of The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature

Abstract Background Colorectal cancer is the third most common and the fourth most lethal cancer in the world. In the majority of cases, patients are diagnosed at an advanced stage or even metastatic, thus explaining the high mortality. The standard treatment for patients with locally advanced non-metastatic rectal cancer is neoadjuvant radio-chemotherapy (NRCT) with 5-fluorouracil (5-FU) followed by surgery, but the resistance rate to this treatment remains high with approximately 30% of non-responders. The lack of evidence available in clinical practice to predict NRCT resistance to 5-FU and to guide clinical practice therefore encourages the search for biomarkers of this resistance. Methods From twenty-three formalin-fixed paraffin-embedded (FFPE) biopsies performed before NRCT with 5-FU of locally advanced non-metastatic rectal cancer patients, we extracted and analysed the tumor proteome of these patients. From clinical data, we were able to classify the twenty-three patients in our cohort into three treatment response groups: non-responders (NR), partial responders (PR) and total responders (TR), and to compare the proteomes of these different groups. Results We have highlighted 384 differentially abundant proteins between NR and PR, 248 between NR and TR and 417 between PR and TR. Among these proteins, we have identified many differentially abundant proteins identified as having a role in cancer (IFIT1, FASTKD2, PIP4K2B, ARID1B, SLC25A33: overexpressed in TR; CALD1, CPA3, B3GALT5, CD177, RIPK1: overexpressed in NR). We have also identified that DPYD, the main degradation enzyme of 5-FU, was overexpressed in NR, as well as several ribosomal and mitochondrial proteins also overexpressed in NR. Data are available via ProteomeXchange with identifier PXD008440. Conclusions From these retrospective study, we implemented a protein extraction protocol from FFPE biopsy to highlight protein differences between different response groups to RCTN with 5-FU in patients with locally advanced non-metastatic rectal cancer. These results will pave the way for a larger cohort for better sensitivity and specificity of the signature to guide decisions in the choice of treatment

Anaïs Chauvin

Chang-Shu Wang

Sameh Geha

Perrine Garde-Granger

Alex-Ane Mathieu

Vincent Lacasse

François-Michel Boisvert

Directory of Open Access Journals

The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature

https://figshare.com/articles/MOESM6_of_The_response_to_neoadjuvant_chemoradiotherapy_with_5-fluorouracil_in_locally_advanced_rectal_cancer_patients_a_predictive_proteomic_signature/6139298

MOESM7 of The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature

Abstract

Similar works

Full text

Available Versions

FigShare

FigShare

FigShare

Directory of Open Access Journals